Log In
BCIQ
Print this Print this
 

PF-06439535

  Manage Alerts
Collapse Summary General Information
Company Pfizer Inc.
DescriptionBiosimilar of bevacizumab, a humanized mAb against VEGF
Molecular Target Vascular endothelial growth factor (VEGF)
Mechanism of ActionVascular endothelial growth factor (VEGF) inhibitor; Antibody; Biosimilar
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPhase III
Standard IndicationNon-small cell lung cancer (NSCLC)
Indication DetailsNon-small cell lung cancer (NSCLC)
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today